Jonathan Liu, Ph.D. joined BeiGene in 2018 and currently serves as Chief Executive, Bio-Island Initiative, and Chairman of the Board, BeiGene Guangzhou Biologics, Ltd. Co. He joined BeiGene from Johnson & Johnson, where he served as Head of China Pharmaceutical Development & Manufacturing Sciences, responsible for its operations and drug development in the Asia-Pacific region. Prior to joining Johnson & Johnson, Dr. Liu spent more than 20 years in industry roles and led drug development projects in CMC, manufacturing, supply chain, R&D, and production facility management. He contributed to developmental milestones for ReFacto®, BENEFIX®, FluMist®, ACAM2000®, and 20 more drug products for Pfizer, Sanofi, AstraZeneca and Novartis.

Dr. Liu holds more than 20 patents in the U.S., Europe, Japan, Australia, and elsewhere. He holds Ph.D. and DVM degrees from Queen’s University in Canada and from the Hunan Agricultural University in China, respectively. He completed his postdoctoral fellowship at Harvard Medical School in the U.S. He has served as a board member of the United States National Center of Therapeutics Manufacturing and various investment firms, biotech companies, trade organizations, and scientific journal review bodies.